Market Overview

Deutsche Bank Initiates ProQR Therapeutics With Buy


Analysts at Deutsche Bank initiated coverage on ProQR Therapeutics (NASDAQ: PRQR) with a Buy rating.

The target price for ProQR Therapeutics is set to $32.

ProQR Therapeutics' shares fell 4% to close at $12.48 yesterday.

Latest Ratings for PRQR

Nov 2019CitiMaintainsBuy
Nov 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Sep 2018Evercore ISI GroupInitiates Coverage OnOutperform

View More Analyst Ratings for PRQR
View the Latest Analyst Ratings


Related Articles (PRQR)

View Comments and Join the Discussion!

Posted-In: Deutsche BankInitiation Analyst Ratings

Latest Ratings

BBCanaccord GenuityMaintains6.0
ATROCanaccord GenuityMaintains14.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at